Vertex is a highly profitable, mature compounder with a dominant franchise in cystic fibrosis generating massive free cash flow. The next phase of growth relies on successfully commercializing its pipeline, including CASGEVY for sickle cell disease and novel pain treatments. Fair value range: low $428, high $722, with mid-point at $574.
Stock analysis
Vertex Pharmaceuticals IncorporatedVRTX Vertex Pharmaceuticals Incorporated fair value $574–$722
Fair value of $574.46 relies on Multi-Stage Moat Fade and DCF models capturing extended moat duration.
Next-phase growth hinges on commercial scaling of CASGEVY and clinical execution of non-opioid pain therapeutics.
Strong balance sheet with $5B in cash/marketables and robust 92% OCF-to-Net-Income conversion.
Fair value
$574
Margin of safety
+25.2%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$429.82Price
FV $574.46
High $721.5
Vertex is a highly profitable, mature compounder with a dominant franchise in cystic fibrosis generating massive free cash flow. The next phase of growth relies on successfully commercializing its pipeline, including CASGEVY for sickle cell disease and novel pain treatments.
Cystic fibrosis therapeutics monopoly with
Cystic fibrosis therapeutics monopoly with high switching costs and IP protection
Specialized distribution and manufacturing scale
Specialized distribution and manufacturing scale
Cycle upside
Biotech expansion phase driven by favorable FDA approvals, loose capital access, and premium valuations assigned to de-risked late-stage assets.
Based on our latest independent analysis, VRTX looks meaningfully undervalued. The current price is $430 versus a composite fair-value midpoint of $574 (range $428–$722), which implies roughly 33.6% upside to the midpoint.
Our composite fair-value range for VRTX is $428–$722, with a midpoint of $574. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for Vertex Pharmaceuticals Incorporated's archetype.
Our current rating for VRTX is Strong Buy with a confidence score of 88/100. Strong Buy. Vertex offers highly visible base cash flows from its CF monopoly combined with compelling optionality from its non-opioid pain and gene-editing pipelines. This is independent research for educational purposes, not personalized investment advice.
The top risks our latest report flags for Vertex Pharmaceuticals Incorporated are: CASGEVY Launch Stalls; Pain Pipeline Failure; CF Monopoly Disruption. The single biggest risk is CASGEVY Launch Stalls: Severe underperformance in commercial scaling of CASGEVY due to treatment center bottlenecks or reimbursement pushback, impairing growth.
Our current rating for VRTX is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($428–$722) versus the current price of $430.
Vertex Pharmaceuticals Incorporated is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for VRTX.
